These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38056137)

  • 1. Redefining Postpartum Depression Treatment: The Clinical Potential of Zuranolone.
    Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan S
    Asian J Psychiatr; 2024 Jan; 91():103849. PubMed ID: 38056137
    [No Abstract]   [Full Text] [Related]  

  • 2. Zuranolone (Zurzuvae) - An oral drug for postpartum depression.
    Med Lett Drugs Ther; 2023 Dec; 65(1692):201-203. PubMed ID: 38133592
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon.
    Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan SF
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110983. PubMed ID: 38412941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.
    Hitt EM
    Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
    Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
    Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
    Winslow M; White E; Rose SJ; Salzer E; Nemec EC
    Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zuranolone: First Approval.
    Heo YA
    Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
    Barnes KN; Vogl CM; Nelson LA
    Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroactive steroids - new possibilities in the treatment of postpartum depression.
    Žigová L; Massarová P; Vranecová K; Hrubá O; Adamičková A; Gažová A
    Ceska Slov Farm; 2022; 71(4):142-150. PubMed ID: 36208918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexanolone and postpartum depression: what does it have to do with GABA?
    Naguy A
    Arch Womens Ment Health; 2019 Dec; 22(6):833-834. PubMed ID: 31302763
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexanolone Therapy for Postpartum Depression.
    Shabbir O; Khan KS; Jawaid H
    J Pak Med Assoc; 2020 Mar; 70(3):565-566. PubMed ID: 32207453
    [No Abstract]   [Full Text] [Related]  

  • 13. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
    Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
    J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexanolone Is the First Drug Specifically for Postpartum Depression.
    Fantasia HC
    Nurs Womens Health; 2019 Oct; 23(5):450-454. PubMed ID: 31445988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexanolone for the treatment of patients with postpartum depression.
    Morrison KE; Cole AB; Thompson SM; Bale TL
    Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
    Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zuranolone: A Breakthrough in the Treatment of Postpartum Depression.
    Diaz ZM; Adashi EY
    J Womens Health (Larchmt); 2024 Apr; 33(4):407-408. PubMed ID: 38306166
    [No Abstract]   [Full Text] [Related]  

  • 18. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
    Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
    Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
    Frieder A; Fersh M; Hainline R; Deligiannidis KM
    CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression.
    Carlini SV; Osborne LM; Deligiannidis KM
    Dialogues Clin Neurosci; 2023 Dec; 25(1):92-100. PubMed ID: 37796239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.